PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC – Expert Perspectives on New Approvals and Emerging Strategies
Season 2, Episode 44, Jul 30, 01:00 PM
Share
Subscribe
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; and Misty D. Shields, MD, PhD; discuss recent advances and emerging approaches—including immunotherapy, DLL3-targeted agents, and antibody-drug conjugates—for patients with small cell lung cancer (SCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
Episode Description
In this podcast, experts Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; and Misty D. Shields, MD, PhD; discuss recent advances and emerging approaches—including immunotherapy, DLL3-targeted agents, and antibody-drug conjugates—for patients with small cell lung cancer (SCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss current trial data describing novel strategies for the management of limited- and extensive-stage SCLC
- Apply clinical trial evidence supporting the efficacy and safety of SCLC treatment across lines of care in real-world case-based scenarios
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Amgen, Inc; AstraZeneca; and Boehringer Ingelheim, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 5789
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
This activity is supported by educational grants from Amgen, Inc; AstraZeneca; and Boehringer Ingelheim, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 5789
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Jonathan W. Goldman, MD
Professor of Medicine, Division of Hematology & Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Drug Development
University of California, Los Angeles
Santa Monica, CA
Disclosures (Dr Goldman): Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Pfizer, Summit; Grant/Research Support: AbbVie, Agenus, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, Janssen, Merck, Pfizer, Puma, RayzeBio, Summit, Tango
Faculty:
Percy Lee, MD, FASTRO
Medical Director, Orange County and Coastal Regions
Department of Radiation Oncology
City of Hope National Medical Center
Irvine, CA
Disclosures: Advisory Board: AstraZeneca, Johnson & Johnson; Consultant: AstraZeneca, Genentech, Johnson & Johnson, Roche; Grant/Research Support: AstraZeneca; Honoraria Recipient: AstraZeneca, Genentech, Johnson & Johnson, Roche
Erminia Massarelli, MD, PhD, MS
Division Chief of Hematology/Oncology
Professor of Medicine
University of Texas Tyler School of Medicine
Tyler, TX
Disclosures (Dr Massarelli): Adviser: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Johnson & Johnson/Janssen, Sanofi; Consultant: AbbVie
Misty D. Shields, MD, PhD
Assistant Professor of Clinical Medicine
Adjunct Assistant Professor of Medical and Molecular Genetics
Associate Member, Experimental and Developmental Therapeutics
Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology
Melvin & Bren Simon Comprehensive Cancer Center
Indiana University School of Medicine
Indianapolis, IN
Disclosures (Dr Shields): Advisory Board: AstraZeneca; Speakers’ Bureau: Jazz Pharmaceuticals; Steering Committee: AstraZeneca
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on new agents and approaches in small cell lung cancer, go to https://www.gotoper.com/annual-oncology-meeting-25-sclc-activity.
Chair:
Jonathan W. Goldman, MD
Professor of Medicine, Division of Hematology & Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Drug Development
University of California, Los Angeles
Santa Monica, CA
Disclosures (Dr Goldman): Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Pfizer, Summit; Grant/Research Support: AbbVie, Agenus, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, Janssen, Merck, Pfizer, Puma, RayzeBio, Summit, Tango
Faculty:
Percy Lee, MD, FASTRO
Medical Director, Orange County and Coastal Regions
Department of Radiation Oncology
City of Hope National Medical Center
Irvine, CA
Disclosures: Advisory Board: AstraZeneca, Johnson & Johnson; Consultant: AstraZeneca, Genentech, Johnson & Johnson, Roche; Grant/Research Support: AstraZeneca; Honoraria Recipient: AstraZeneca, Genentech, Johnson & Johnson, Roche
Erminia Massarelli, MD, PhD, MS
Division Chief of Hematology/Oncology
Professor of Medicine
University of Texas Tyler School of Medicine
Tyler, TX
Disclosures (Dr Massarelli): Adviser: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Johnson & Johnson/Janssen, Sanofi; Consultant: AbbVie
Misty D. Shields, MD, PhD
Assistant Professor of Clinical Medicine
Adjunct Assistant Professor of Medical and Molecular Genetics
Associate Member, Experimental and Developmental Therapeutics
Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology
Melvin & Bren Simon Comprehensive Cancer Center
Indiana University School of Medicine
Indianapolis, IN
Disclosures (Dr Shields): Advisory Board: AstraZeneca; Speakers’ Bureau: Jazz Pharmaceuticals; Steering Committee: AstraZeneca
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on new agents and approaches in small cell lung cancer, go to https://www.gotoper.com/annual-oncology-meeting-25-sclc-activity.
Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.